Table 1 Demographic and clinical features of patients
Characteristics | Subjects (n = 47) | |
|---|---|---|
Female, n (%) | 35 | (74.5) |
Chinese, n (%) | 43 | (91.5) |
Malay, n (%) | 4 | (8.5) |
Smoking, n (%) | ||
Non-smoker | 29 | (69.1) |
Ex-smoker | 9 | (20.5) |
Current smoker | 4 | (9.1) |
Presence of family history of thyroid disease, n (%) | 24 | (53.3) |
Mean age at diagnosis, years (SD) | 38.5 | (14.1) |
Mean duration of condition, years (SD) | 5.5 | (10.2) |
Immunological diagnosis | ||
Thyrotropin Stimulating Hormone Receptor Antibody Positive | 46 | (97.9) |
Thyroid Stimulating Immunoglobulin Positive | 1 | (2.1) |
Symptoms of hyperthyroidism | ||
General, n (%) | 31 | (67.4) |
Cardiorespiratory, n (%) | 34 | (72.3) |
Gastrointestinal, n (%) | 33 | (70.2) |
Neurological, n (%) | 28 | (59.6) |
Eye, n (%) | 12 | (25.5) |
Constitutional, n (%) | 14 | (29.8) |
Signs of hyperthyroidism | ||
Heart rate, bpm (SD) | 91 | (21.6) |
Goitre, n (%) | 28 | (62.2) |
Clinical hyperthyroidism, n (%) | 31 | (70.5) |
Biochemical and Ultrasound | ||
Mean free thyroxine, pmol/L (SD) | 45.9 | (22.0) |
Median TSH, mIU/L (IQR)- Range 0.00249–0.22 | 0.02 | (0.01–0.03) |
Mean TRAb, IU/L (SD) | 16.0 | (13.3) |
Thionamide treatment | ||
Propylthiouracil, mg/day (SD) | 90 | (42) |
Carbimazole, mg/day (SD) | 16 | (8) |